Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro
Clinical and Translational Science · 2025-02 · 18 (2)
DOI: 10.1111/cts.70152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 07.02.2025. Verfasst von Gerald C So und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Tacrolimus, Cannabidiol, Cytochrome P-450 CYP3A Inhibitors, Immunosuppressive Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCCIH NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Drug interactions are major causes of interindividual variability in tacrolimus exposure and effect. Tacrolimus, a widely used drug in transplant patients, is metabolized by CYP3A4 and CYP3A5. Cannabidiol (CBD) use after transplant is common. Clinical cases suggest CBD may alter tacrolimus exposure, but the mechanism of this interaction is unknown. We hypothesize that cannabidiol will inhibit tacrolimus metabolism in vitro mainly through CYP3A5 inhibition. In pooled human liver microsomes (HLMs) and recombinant (r) CYP3A4 and CYP3A5 enzymes, tacrolimus (1 μM) metabolism was determined using substrate depletion method in the absence (control) and the presence of 10 μM CBD, 7‐hydroxyCBD, and 7‐carboxyCBD. Ketoconazole (1 μM) served as a positive control for the inhibition of CYP3A. Linear regression analyses were performed to obtain kinetic parameters of the depletion. Tacrolimus depletion half‐life was 2.54, 0.922, and 0.351 min with pooled HLMs, rCYP3A4, and rCYP3A5, respectively. In pooled HLMs, CBD and 7‐hydroxyCBD increased tacrolimus half‐life by 0.8‐ and 2.3‐fold (both p < 0.0001), respectively. In rCYP3A4, CBD, 7‐hydroxyCBD, and ketoconazole prolonged tacrolimus half‐life by 5.8‐, 14‐, and 7.7‐fold, respectively. In rCYP3A5, CBD, 7‐hydroxyCBD, and ketoconazole prolonged half‐life by 29.3‐, 19.7‐, and 0.1‐fold, respectively. In all experiments, 7‐carboxyCBD had minimal effect on tacrolimus depletion. CBD and 7‐hydroxyCBD inhibited tacrolimus metabolism in vitro. CBD showed stronger inhibition in rCYP3A5 than rCYP3A4. The demonstrated CYP3A5 selectivity of cannabidiol may contribute to the in vitro identification of CYP3A5 substrates in new drug development. Our results support the potential of a clinical drug–drug interaction between CBD and tacrolimus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Gerald C So, Sachiko Koyama, Zeruesenay Desta, Michael T Eadon
Förderung
- NCCIH NIH HHS
- NIGMS NIH HHS
Zitieren
APA
So, G. C., Lu, J. B. L., Cheng, Y. H., Gisch, D. L., Koyama, S., Melo Ferreira, R., Beamon, T. R., Desta, Z., & Eadon, M. T. (2025). Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro. Clinical and Translational Science, 18(2). https://doi.org/10.1111/cts.70152
Vancouver
So GC, Lu JBL, Cheng YH, Gisch DL, Koyama S, Melo Ferreira R, et al. Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro. Clinical and Translational Science. 2025;18(2). doi:10.1111/cts.70152
BibTeX
@article{So2025,
author = {So, Gerald C and Lu, Jessica Bo Li and Cheng, Ying-Hua and Gisch, Debora L and Koyama, Sachiko and Melo Ferreira, Ricardo and Beamon, Travis R and Desta, Zeruesenay and Eadon, Michael T},
title = {Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro},
journal = {Clinical and Translational Science},
year = {2025},
volume = {18},
number = {2},
doi = {10.1111/cts.70152}
}
EUVIMED